Abbott announced that it received approval from the U.S. FDA to launch the Liberta RC DBS system, the world’s smallest rechargeable deep brain stimulation device with remote programming, to treat people living with movement disorders.1+ The Liberta RC DBS system also requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott (NYSE:ABT) Drops on Q4 Results
- Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
- Abbott sees FY24 adjusted EPS $4.50-$4.70, consensus $4.64
- Abbott reports Q4 worldwide Medical Devices sales up 17.5% on reported basis
- Abbott reports Q4 adjusted EPS $1.19, consensus $1.19
